"Dr. Gutierrez's significant immuno-oncology experience will be transformative to Oncolytics. His expertise spans a range of indications and drug types that are immediately applicable to his new role and the clinical programs at Oncolytics," said Dr. Matt Coffey, Interim President and CEO of Oncolytics Biotech. "In addition to specific experience with carfilzomib and immuno-checkpoint-inhibitors in the treatment of multiple myeloma and diverse malignancies, respectively, he has extensive experience in the design and implementation of clinical programs, including registration studies, interacting with regulatory bodies globally, and establishing strong relationships with key opinion leaders."

"The addition of Dr. Gutierrez as CMO marks an important step towards establishing a well-articulated clinical plan with a clear registration strategy under Dr. Coffey's leadership," said Wayne Pisano, Chair of the Board of Oncolytics.

"The field of immunotherapy is now at a crossroads, trying to identify the next-generation weapons poised to further enhance the immune system to fight cancer," said Dr. Andres A. Gutierrez, Chief Medical Officer of Oncolytics. "Extending the depth and quality of responses requires better exploiting the interplay and hierarchy of the innate and adaptive immune responses to design more powerful immune therapies. Oncolytics and its collaborators have shown that REOLYSIN ® has both a tumor-priming effect, which can improve the efficacy of other therapeutic agents, including check point inhibitors, and that it can work within a dose range that has a favorable safety profile even when combined with such other therapeutic agents. This suggests that REOLYSIN ® has real potential in combination with other immune-modulators and/or targeted therapies to improve not only the current clinical outcomes but the quality of life for a wide array of cancer patients. It is an exciting time to join Oncolytics and I am very eager to share my experience in drug development in its mission to help patients."